The antischistosomal potential of GSK-J4, an H3K27 demethylase inhibitor: insights from molecular modeling, transcriptomics and in vitro assays

BACKGROUND: Schistosomiasis chemotherapy is largely based on praziquantel (PZQ). Although PZQ is very safe and tolerable, it does not prevent reinfection and emerging resistance is a primary concern. Recent studies have shown that the targeting of epigenetic machinery in Schistosoma mansoni may resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lobo-Silva, Jessica, Cabral, Fernanda J., Amaral, Murilo S., Miyasato, Patrícia A., de Freitas, Rafaela Paula, Pereira, Adriana S. A., Khouri, Mariana I., Barbosa, Mayra M. F., Ramos, Pablo I. P., Leite, Luciana C. C., Asojo, Oluwatoyin A., Nakano, Eliana, Verjovski-Almeida, Sergio, Farias, Leonardo P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077139/
https://www.ncbi.nlm.nih.gov/pubmed/32178714
http://dx.doi.org/10.1186/s13071-020-4000-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077139/
https://www.ncbi.nlm.nih.gov/pubmed/32178714
http://dx.doi.org/10.1186/s13071-020-4000-z

Ejemplares similares